Type 1 Diabetes: Etiology, Presentation, Management, and Emerging Therapies

Autoimmune Beta-Cell Destruction: A Lifelong Insulin Dependence

Type 1 diabetes (T1D) affects 1.6M Americans (including 200,000 youth). Incidence rising 2–3%/yr globally. It is not preventable — yet.

Pathogenesis

  • Genetic susceptibility: HLA-DR3/DQ2 & DR4/DQ8 haplotypes (40–50% familial risk). >50 non-HLA loci identified.
  • Environmental triggers: Enteroviruses (coxsackie B), early cow's milk/gluten (debated), vitamin D deficiency, microbiome alterations, hygiene hypothesis.
  • Autoimmunity: Islet autoantibodies (GAD65, IA-2, ZnT8, IAA, ICA) appear years before clinical onset. Stage 1: ≥2 autoantibodies, normoglycemia. Stage 2: + dysglycemia. Stage 3: symptomatic T1D.

Clinical Presentation

  • Classic: Polyuria, polydipsia, weight loss, fatigue, blurred vision (weeks-months).
  • DKA at diagnosis: 30–40% (higher in <5 yrs, minorities, uninsured).
  • Adult-onset (LADA): Slower progression, often misdiagnosed as T2D. Test GAD65 + C-peptide.

Diagnostic Criteria

  • Hyperglycemia criteria (same as T2D) +
  • Autoantibodies (+) and/or
  • Low/undetectable C-peptide (fasting or stimulated) +
  • Clinical context (ketosis, age, acuity)

Modern Management Pillars

  1. Insulin replacement: Basal-bolus (MDI: glargine/degudec + lispro/aspart/glulisine) or CSII (pump). Ultra-rapid insulins (fiasp, lyumjev) improve postprandial control.
  2. CGM + Automated Insulin Delivery (AID): Hybrid closed-loop systems (Tandem t:slim X2 Control-IQ, Medtronic 780G, Omnipod 5, CamAPS FX) adjust basal q5min per CGM. Game-changer: ↑ TIR, ↓ hypoglycemia, ↓ burden.
  3. Glucose monitoring: CGM standard of care (ADA). SMBG for calibration/verification.
  4. Nutrition: Carb counting (insulin:carb ratio), insulin sensitivity factor. Flexible eating with AID.
  5. Physical activity: Adjust insulin/carbs per exercise type/intensity; CGM alerts prevent exercise hypoglycemia.
  6. Psychosocial: Diabetes distress (40%), depression, eating disorders (diabulimia). Screen annually; refer.

Acute Complications

  • DKA: Hyperglycemia + ketosis + acidosis. Prevent: sick-day rules, ketone monitoring (blood β-OHB), CGM alerts, never omit basal insulin.
  • Severe hypoglycemia: Glucagon (nasal Baqsimi, autoinjector Gvoke, dasiglucagon Zegalogue) — teach caregivers.

Long-Term Complications & Screening

Same as T2D but earlier onset = longer exposure. Intensive control (DCCT) → 50–76% risk reduction for retinopathy, nephropathy, neuropathy. CVD risk 10× age-matched.

Disease-Modifying Horizons

  • Teplizumab (anti-CD3): FDA-approved (2022) to delay Stage 3 T1D in Stage 2 (≥8 yrs). Median delay 2–3 years.
  • Beta-cell replacement: Stem cell-derived islets (Vertex VX-880) + immunosuppression / encapsulation — Phase 1/2.
  • Immunotherapies: Abatacept, alefacept, low-dose IL-2, TCR-targeted — preservation trials.
  • Prevention: Primary (antigen-specific tolerance), secondary (teplizumab), tertiary (new-onset preservation).

Hope with realism: T1D is demanding, but technology and therapeutics are advancing rapidly. People with T1D thrive as athletes, physicians, parents, centenarians. Community (JDRF, Beyond Type 1, T1D Exchange) is a powerful resource.

Diabetes - Related Articles